253426-24-3

Basic information

• Product Name: AVE8062A
• Synonyms: AVE8062A;AC 7700;Ombrabulin (hydrochloride);Ombrabulin (AVE8062) HCl
• CAS NO: 253426-24-3
• Molecular Formula: C₂₁H₂₆N₂O₆*ClH
• Molecular Weight: 438.90188
• EINECS: -0
• Mol File: 253426-24-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: AVE8062A(CAS DataBase Reference)
• NIST Chemistry Reference: AVE8062A(253426-24-3)
• EPA Substance Registry System: AVE8062A(253426-24-3)

Safety Data

• RTECS: TX1404540
• Hazardous Substances Data: 253426-24-3(Hazardous Substances Data)

Usage

Biochem/physiol Actions

Ombrabulin is a synthetic water-soluble combretastatin analog vascular disrupting agent. Ombrabulin is a tubulin polymerization inhibitor. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells.

Upstream product

• 181816-48-8 (S,Z)-2-amino-3-hydroxy-N-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)propanamide 
• 61240-20-8 triphenyl-(3,4,5-trimethoxybenzyl)phosphonium bromide 
• 162705-07-9 3-amino-deoxycombretastatin A₄ 
• 162705-13-7 (Z)-1-(4''-methoxy-3''-nitrophenyl)-2-(3',4',5'-trimethoxyphenyl)ethene 
• 286463-65-8 (S,Z)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)amino)-3-oxopropyl acetate 
• 3840-31-1 (3,4,5-trimethoxyphenyl)methanol 
• 21852-50-6 3,4,5-trimethoxybenzyl bromide 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 

Relevant articles and documents

Compositions and Methods for Treatment of Cancer

Resistance of randomly dispersed and oxygen-starved lung tumor cells to chemo- and radiotherapy constitutes the vast majority recurrences and death from lung cancer. We use sickle cells derived from humans with sickle cell anemia to target oxygen-deprived

Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents

Targeting tumor vasculature represents an intriguing therapeutic strategy in the treatment of cancer. In an effort to discover new vascular disrupting agents with improved water solubility and potentially greater bioavailability, various amino acid prodru

COMBRETASTATIN DERIVATIVE PREPARATION METHOD

The invention relates to a method for preparing a combretastatin derivative (I) or (II), said method including the following steps: triaryl(3,4,5-trimethoxybenzyl)phosphonium halide P3 (III), wherein Ar denotes an aryl group selected from among phenyl or thienyl, is reacted with P2 having formula (IV) or P′2 having formula (V) so as to respectively obtain the compound P4 or P′4, which have formulas (VI) and (VII), respectively; then, during a step for deprotection in the presence of an acid and/or a base, the compound having P4 or P′4 leads, after an optional purification step, to the compound having formula (I) or (II).

Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs

Several derivatives of combretastatin have been prepared bearing a cyclopropyl unit instead of the natural occurring cis-double bond. Final products and synthetic intermediates were evaluated for their cytotoxic properties in two human cancer cell lines.